Pre-approval Expanded Access of Retatrutide (LY3437943)

Not applicable study, condition: Obesity, Obesity-related Complications. Provide pre-approval single-patient expanded access of retatrutide (LY3437943), an investigational GLP-1/GIP/glucagon triple receptor agonist being studied for chronic weight management, for adults with severe obesity (body mass index \[BMI\] greater than or equal to \[≥\]35 kilogram per square meter \[kg/m²\] and at least two serious or life-threatening obesity-related complications who are refractory to the best approved therapy and are unable to participate in an ongoing clinical trial of retatrutide or a comparable investigational medicine. Status: available (expanded access). No topline or peer-reviewed results are verified for publication on this Record for this study — registry facts only.